Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.
Shulman NS, Machekano RA, Shafer RW, Winters MA, Zolopa AR, Liou SH, Hughes M, Katzenstein DA; AIDS Clinical Trials Group 302 Study Team. Shulman NS, et al. Among authors: katzenstein da. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):377-80. doi: 10.1097/00126334-200108010-00008. J Acquir Immune Defic Syndr. 2001. PMID: 11468426 Clinical Trial.
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA. Shulman NS, et al. Among authors: katzenstein da. J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):121-7. doi: 10.1097/00126334-200210010-00001. J Acquir Immune Defic Syndr. 2002. PMID: 12394789 Clinical Trial.
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. Shafer RW, et al. Among authors: katzenstein da. J Infect Dis. 1995 Jul;172(1):70-8. doi: 10.1093/infdis/172.1.70. J Infect Dis. 1995. PMID: 7541064 Clinical Trial.
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.
Shulman NS, Zolopa AR, Passaro DJ, Murlidharan U, Israelski DM, Brosgart CL, Miller MD, Van Doren S, Shafer RW, Katzenstein DA. Shulman NS, et al. Among authors: katzenstein da. J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):221-6. doi: 10.1097/00126334-200003010-00002. J Acquir Immune Defic Syndr. 2000. PMID: 10839657
Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.
Katzenstein DA, Hughes M, Albrecht M, Hammer S, Para M, Murphy R, Valdez H, Haubrich R, Liou S. Katzenstein DA, et al. AIDS Res Hum Retroviruses. 2000 Jul 20;16(11):1031-7. doi: 10.1089/08892220050075282. AIDS Res Hum Retroviruses. 2000. PMID: 10933617 Clinical Trial.
299 results